

Free reagents and services through EURIPRED

Recombinant protein	Lipoalvacan	Antibody	ELISA kit	Peptides mix	Peptide microarray	Clinical sample	SNF	Plasmids
UG37gp140, CN54gp140, UG21gp140, BR29gp140, HIV tat cons. C, HIV tat Ba-L		Anti gp41: 2F5, 3D6, 4E10, 5F3, 4B3, 246-D, F240, Z13e1 Anti gp120: 2G12, M1G1 (anti-2G12), b12, PG9, PG16, 447-52D Anti p24: 37G12, M01, N17, N29 Anti nef: 2F2, N5		HIV-1 NEF HIV-1 GAG	HIV Ultra	90 HIV+ plasma	40 HIV+ SNF	17 env. clones
HIV								
ESAT6, CFP10, MPT64, PstS1, 85A, 16 kDa, MPB83, HSP65, 85B, TB10.4, Rv0569, 1733, 1735, 1737, 2005, 2029, 2032, 2626, 2627, 2628, 2034, 3353, 0867, 1009, 2389, 2660	<i>M. bovis</i> LAM <i>M. bovis</i> LM <i>M. bovis</i> PIM <i>M. Tuberculosis</i> LAM <i>M. Tuberculosis</i> LM <i>M. Tuberculosis</i> PIM		CFP10 IgM antibody CFP10 IgA antibody CFP10 IgG antibody ESAT6 IgM antibody ESAT6 IgA antibody ESAT6 IgG antibody	ESAT6			50 TB isolates	
TB								
HCV soluble E2 (H77)	e137 (HCV neutralising Ab)				HBV Ultra			
HBV/HCV								

EURIPRED (European Research Infrastructures for Poverty Related Diseases) supports European scientists with FREE access to reference reagents, services and training.

www.euripred.eu/free-services

EURIPRED facilitates and supports translational research for poverty related diseases, such as HIV, TB, malaria and hepatitis with offering access to free services including:

- Access to biological materials and reference reagents/standards facilitated by the National Institute of Biological Standards and Control (NIBSC), UK;
- Access to vaccine adjuvant & formulation studies, facilitated by the University of Lausanne, Switzerland;
- Access to microarray facility for screening & evaluation facilitated by JPT Peptide Technologies, Germany.

Besides EURIPRED products, the products in the CFAR Catalogue are also available for free access <http://www.euripred.eu/free-services/reference-standards-and-reagents-platform.html>

Application procedure

EURIPRED operates continues call for free services access to reagents and microarray facility. Applications may be submitted at any time and will be evaluated within a maximum of three weeks upon receipt by the EURIPRED Project Team.

Please note that for access to vaccine adjuvant & formulation studies, the deadline is on 15 Feb 2017.

More details on the services and procedure can be found on the EURIPRED website

www.euripred.eu/free-services/call-procedure.html

Contact information:

Yann Le Duff (EURIPRED project team)
yann.leduff@nibsc.org

EURIPRED is co-funded with € 8.5 million by the European Commission. Scientists from 17 research partners in 10 countries collaborate in this programme. The project started in November 2013, is a 4-year project and has received funding from the European Union's Seventh Programme for research, technological development and demonstration under grant agreement No 312661.

www.euripred.eu